XOMA/$XOMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About XOMA
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Ticker
$XOMA
Sector
Primary listing
Employees
13
Headquarters
Website
XOMA Metrics
BasicAdvanced
$448M
-
-$1.37
1.00
-
Price and volume
Market cap
$448M
Beta
1
52-week high
$38.34
52-week low
$18.35
Average daily volume
56K
Financial strength
Current ratio
4.881
Quick ratio
4.854
Long term debt to equity
110.8
Total debt to equity
123.935
Interest coverage (TTM)
-1.31%
Profitability
EBITDA (TTM)
-16.345
Gross margin (TTM)
93.23%
Net profit margin (TTM)
-21.47%
Operating margin (TTM)
-39.51%
Effective tax rate (TTM)
36.95%
Revenue per employee (TTM)
$3,460,000
Management effectiveness
Return on assets (TTM)
-4.76%
Return on equity (TTM)
-10.03%
Valuation
Price to revenue (TTM)
9.81
Price to book
6.18
Price to tangible book (TTM)
16.6
Price to free cash flow (TTM)
-15.233
Free cash flow yield (TTM)
-6.56%
Free cash flow per share (TTM)
-2.435
Growth
Revenue change (TTM)
194.98%
Earnings per share change (TTM)
-36.86%
3-year revenue growth (CAGR)
3.14%
10-year revenue growth (CAGR)
11.85%
3-year earnings per share growth (CAGR)
19.99%
10-year earnings per share growth (CAGR)
-20.80%
What the Analysts think about XOMA
Analyst ratings (Buy, Hold, Sell) for XOMA stock.
Bulls say / Bears say
XOMA reported net income of $2.4 million for Q1 2025, compared with a net loss of $8.6 million in Q1 2024, showing clear progress toward sustained profitability. (Reuters)
The company made a strategic $5 million royalty investment in Castle Creek Biosciences’ D-Fi (FCX-007), a Phase 3 asset with Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy designations. (Reuters)
XOMA received a $4 million milestone from the EMA's acceptance of tovorafenib’s MAA and a $3 million milestone on the launch of Takeda's Phase 3 mezagitamab trial, highlighting strong execution from partners. (Reuters)
Cash and equivalents dropped to $95.0 million as of March 31, 2025, down from $106.4 million at the end of 2024, signaling significant capital outlay that could limit financial flexibility. (Reuters)
General and administrative expenses remained high at $8.1 million in Q1 2025, only a slight improvement over $8.5 million in Q1 2024, which may squeeze margins as royalty income normalizes. (Reuters)
A large share of Q1 cash inflows—$4.6 million out of $18.0 million—came from milestone and fee payments, implying that future earnings could be volatile and dependent on unpredictable regulatory events. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
XOMA Financial Performance
Revenues and expenses
XOMA Earnings Performance
Company profitability
XOMA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for XOMA stock?
XOMA (XOMA) has a market cap of $448M as of September 17, 2025.
What is the P/E ratio for XOMA stock?
The price to earnings (P/E) ratio for XOMA (XOMA) stock is 0 as of September 17, 2025.
Does XOMA stock pay dividends?
No, XOMA (XOMA) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next XOMA dividend payment date?
XOMA (XOMA) stock does not pay dividends to its shareholders.
What is the beta indicator for XOMA?
XOMA (XOMA) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.